CytoMed Therapeutics Limited (NASDAQ:GDTC) Sees Large Decline in Short Interest

CytoMed Therapeutics Limited (NASDAQ:GDTC) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 5,655 shares, a drop of 81.2% from the July 15th total of 30,057 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 329,145 shares, the short-interest ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

CytoMed Therapeutics Trading Up 5.1%

Shares of NASDAQ:GDTC opened at $0.84 on Wednesday. The firm has a fifty day moving average of $1.00 and a two-hundred day moving average of $1.01. CytoMed Therapeutics has a 12-month low of $0.68 and a 12-month high of $3.68. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.